Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study

Cardoso, F.Juric, D.Lerebours, F.Krop, I.Borrego, M. RuizNeven, P.Park, Y. H.Yardley, D.Jhaveri, K.Arce, C.Gu, E.Akdere, M.Rugo, H. S.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21904enAlpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve studyconference outputopen access10.1016/j.annonc.2022.03.1941569-8041http://www.annalsofoncology.org/article/S0923753422005737/pdf792494100178